Latest News & Features
Americas
A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process. 2 July 2026
Careers
The firm has appointed two new partners in Basel and Bristol, adding decades of expertise from the pharmaceutical and biotech sectors to its growing life sciences practice. 2 July 2026
Big Pharma
Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country. 1 July 2026
Careers
A first-chair trial lawyer with two decades in high-stakes patent and trade secret disputes brings experience across medical devices, biologics, and pharmaceuticals, alongside a broader technology-focused practice. 1 July 2026
Americas
Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market. 30 June 2026
Careers
The latest additions bring experience representing technology and medical device companies in complex patent and commercial disputes, with the firm extending its run of bringing in partners from Winston & Strawn before its merger. 30 June 2026
Careers
The newly combined transatlantic firm brings together more than 950 partners across 20 countries, uniting leading patent, trade secrets, life sciences, and tech practices. 29 June 2026
Biotechnology
Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies. 26 June 2026
Americas
The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences. 25 June 2026
Biotechnology
Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines. 25 June 2026